Epithelial Tumor Clinical Trials

1 recruiting

Epithelial Tumor Trials at a Glance

17 actively recruiting trials for epithelial tumor are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Shanghai, Beijing, and Bedford Park. Lead sponsors running epithelial tumor studies include Jian Chen, Erasmus Medical Center, and CNAO National Center of Oncological Hadrontherapy.

Browse epithelial tumor trials by phase

Treatments under study

About Epithelial Tumor Clinical Trials

Looking for clinical trials for Epithelial Tumor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epithelial Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epithelial Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Thymic Epithelial TumorThymic CancerRecurrent Thymoma
National Cancer Institute (NCI)53 enrolled1 locationNCT05104736
Recruiting
Not Applicable

Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors

Epithelial Tumors, Malignant
Peking University People's Hospital30 enrolled1 locationNCT07400263
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 1Phase 2

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Lung CancersLocally AdvancedSolid Tumor Cancer+2 more
Avenzo Therapeutics, Inc.430 enrolled16 locationsNCT07038343
Recruiting
Not Applicable

Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies

Tumor RecurrenceMalignant Epithelial Neoplasm of VulvaMalignant Epithelial Tumor of Ovary+1 more
CNAO National Center of Oncological Hadrontherapy55 enrolled1 locationNCT05457595
Recruiting
Phase 2

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+7 more
Ira Winer62 enrolled2 locationsNCT04055649
Recruiting
Phase 2

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Radiotherapy Side EffectThymic Epithelial TumorCarbon Ion Radiotheray+1 more
Jian Chen48 enrolled1 locationNCT06311955
Recruiting
Phase 2

The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Radiation ToxicityProton RadiotherapyThymus Epithelial Tumor
Jian Chen55 enrolled1 locationNCT06311968
Recruiting

Molecular Analysis and Treatment Options of Thymic Malignancies

Thymic CarcinomaThymic Epithelial TumorThymic Cancer
Shanghai Chest Hospital500 enrolled1 locationNCT05667948
Recruiting

Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach

CavernomaPilocytic AstrocytomaGanglioglioma+6 more
University Hospital, Montpellier3,504 enrolled1 locationNCT06915649
Recruiting
Not Applicable

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

ThymomaThymic Epithelial TumorThymoma and Thymic Carcinoma+1 more
Rongrong Zhou100 enrolled1 locationNCT06692062
Recruiting
Early Phase 1

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Epithelial Tumors, MalignantMalignant Solid Tumor
Vall d'Hebron Institute of Oncology10 enrolled1 locationNCT05141474
Recruiting

Establishing Prospective Mediastinal Tumor Database of PUMCH

Germ Cell TumorLymphomaThymic Epithelial Tumor+4 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT06421805
Recruiting

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

ThymomaThymic CarcinomaThymic Epithelial Tumor+1 more
Erasmus Medical Center1,020 enrolled1 locationNCT06301945
Recruiting
Phase 1

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Epithelial Tumors, Malignant
Myeloid Therapeutics48 enrolled6 locationsNCT05969041
Recruiting
Phase 2

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian NeoplasmsUrogenital NeoplasmsCarcinoma, Ovarian Epithelial+5 more
Sheba Medical Center24 enrolled1 locationNCT04519151
Recruiting

Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer

Esophageal Squamous Cell CarcinomaNSCLCThymic Epithelial Tumor
Shanghai Cancer Hospital, China500 enrolled1 locationNCT04522687